Gliperin

Gliperin is an oral medication containing the active ingredient glimepiride, a sulfonylurea used to manage blood glucose levels in adults with type 2 diabetes mellitus. It is supplied in tablet form (strength not specified) and is marketed in the European Union. Gliperin works by stimulating insulin release from pancreatic beta cells, helping to lower elevated blood sugar. It is available by prescription only through medical supervision.

Gliperin is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

- As monotherapy for patients with newly diagnosed type 2 diabetes. - In combination with metformin when metformin alone does not achieve target glucose levels. - As part of a fixed‑dose combination regimen with other oral antidiabetic agents. - To improve fasting and post‑prandial blood glucose concentrations. - For use in patients whose renal function permits sulfonylurea therapy.

Gliperin may cause a range of adverse effects, most of which are mild and transient, while rare events can be serious and require medical attention.

Common: - Mild hypoglycemia, especially when meals are skipped or delayed. - Nausea or abdominal discomfort. - Headache or dizziness. - Weight gain due to increased insulin activity. - Transient fatigue or weakness.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions such as rash, itching, or swelling. - Hematologic abnormalities like leukopenia or thrombocytopenia. - Hepatic dysfunction presenting as jaundice or elevated liver enzymes. - Pancreatitis with abdominal pain and elevated enzymes.

Before initiating Gliperin therapy, healthcare providers should evaluate patient-specific factors and monitor for conditions that may increase the risk of adverse outcomes.

- Assess renal and hepatic function; dose adjustments may be needed in impairment. - Review history of cardiovascular disease, as sulfonylureas can affect cardiac ischemia. - Caution in elderly patients due to higher susceptibility to hypoglycemia. - Avoid use during pregnancy and lactation unless benefits outweigh risks. - Monitor blood glucose regularly to detect hypoglycemia early. - Consider potential for weight gain and adjust lifestyle counseling accordingly. - Screen for allergic reactions if the patient has known sulfonylurea sensitivity.

Gliperin can interact with several medicines, altering blood glucose levels or increasing the risk of side effects; awareness of these interactions helps ensure safe use.

Avoid: - Concurrent use with other sulfonylureas or insulin, which may cause severe hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise glimepiride concentrations. - MAO‑B inhibitors, which can potentiate hypoglycemic effects.

Use with caution: - Beta‑blockers, as they may mask hypoglycemia symptoms. - Thiazide diuretics, which can affect glucose tolerance. - Oral contraceptives, potentially altering glimepiride metabolism. - Antifungal agents like itraconazole, requiring closer glucose monitoring.